, /PRNewswire/ -- Ridgetech, Inc. (Nasdaq:RDGT) ("Ridgetech" or the "Company"), a wholesale distributor of pharmaceutical and other healthcare products inChina, today announced its financial results for the fiscal year endedMarch 31, 2025.

, /PRNewswire/ -- Ridgetech, Inc. (Nasdaq:RDGT)（“Ridgetech” 或 “公司”），是一家在中國的藥品及其他醫療產品的批發分銷商，今天公佈了截至2025年3月31日的財務業績。

Mr. Frank Zhao, Interim Chief Executive Officer and Chief Financial Officer of Ridgetech, commented, "We are pleased to present a relatively stable revenue outcome for fiscal year 2025, a year marked by significant transformation for the Company. During this period, we divested our retail pharmacy business and acquired Ridgeline and its subsidiary, Allright (Hangzhou) Internet Technology Co. Ltd ("Allright"), marking our strategic expansion into both online and offline wholesale distribution of pharmaceutical and healthcare products in China.

Ridgetech 的臨時首席執行官兼首席財務官 Frank Zhao 先生評論道：“我們很高興地呈現 2025 財年的相對穩定的收入結果，這一年對公司而言是一個重大轉型的年份。在此期間，我們剝離了零售藥房業務，並收購了 Ridgeline 及其子公司 Allright（杭州）互聯網科技有限公司（“Allright”），標誌着我們在中國藥品和醫療產品的線上和線下批發分銷的戰略擴展。

This move reflects our commitment to shift our resources focus onto the wholesale pharmaceutical sector, aligning with the evolving landscape and intensifying competition in China's healthcare industry. We believe Allright's broad and growing online and offline distribution network will rapidly become an indispensable contributor to our revenue and open up new business opportunities through its multiple platforms.

這一舉措反映了我們將資源重點轉向批發藥品領域的承諾，以適應中國醫療行業不斷變化的格局和日益激烈的競爭。我們相信 Allright 廣泛且不斷增長的線上和線下分銷網絡將迅速成為我們收入的重要貢獻者，並通過其多個平台開闢新的商業機會。

Despite the scale of change in fiscal year 2025, we maintained stable total revenue of approximately US$120 million, while securing healthy profit margins across both our offline wholesale operations and online platforms. Notably, revenue from Allright's own and third-party online platforms -- only reflecting activity from March 2025 following our acquisition on February 28, 2025 -- already contributed nearly 1% of our total revenue, with a gross margin of 7.4%.

儘管 2025 財年發生了大規模的變化，我們仍保持了約 1.2 億美元的穩定總收入，同時在我們的線下批發業務和在線平台上確保了健康的利潤率。值得注意的是，Allright 自有及第三方在線平台的收入——僅反映我們在2025年2月28日收購後 2025 年 3 月的活動——已貢獻了我們總收入的近 1%，毛利率為 7.4%。

To support this strategic shift, we increased our investment in sales and marketing by 64.2%, primarily to build a stronger foundation for post-transformation growth.

為了支持這一戰略轉型，我們將銷售和市場營銷的投資增加了 64.2%，主要是為了為轉型後的增長奠定更強的基礎。

Looking ahead, with the completion of our strategic transformation and continued progress in integrating our business segments and internal resources, we believe Ridgetech is now better positioned to drive long-term sustainable growth and deliver improved financial performance."

展望未來，隨着我們戰略轉型的完成以及在整合業務部門和內部資源方面的持續進展，我們相信 Ridgetech 現在更有能力推動長期可持續增長並實現改善的財務表現。”

Fiscal Year 2025 Financial Summary

2025 財年財務摘要

In accordance with ASC 205, the Company has classified the historical retail operations, primarily conducted through Zhejiang Jiuxin Investment Management Co., Ltd. ("Jiuxin Investment") and its controlled entities, as discontinued operations and has re-presented prior periods accordingly. As a result, the comparative figures in this release reflect these adjustments and may differ from those previously reported.

根據 ASC 205，公司已將通過浙江九信投資管理有限公司（“九信投資”）及其控制實體主要進行的歷史零售業務分類為終止經營，並相應地重新呈現了之前的期間。因此，本公告中的比較數據反映了這些調整，可能與之前報告的數據有所不同。

Revenue was$119.97 millionfor the fiscal year endedMarch 31, 2025, compared to$123.99 millionfor the same period of last year.
Gross profit was$3.84 millionfor the fiscal year endedMarch 31, 2025, compared to$4.88 millionfor the same period of last year.
Gross margin was 3.2% for the fiscal year endedMarch 31, 2025, compared to 3.9% for the same period of last year.
Net income was$10.20 million, or$1.84per basic and diluted earnings per share, for the fiscal year endedMarch 31, 2025, compared to net loss of$4.23 million, or$2.93per basic and diluted loss per share, for the same period of last year.

截至2025年3月31日的財年，收入為 1.1997 億美元，較去年同期的 1.2399 億美元下降。
截至2025年3月31日的財年，毛利潤為 384 萬美元，較去年同期的 488 萬美元下降。
截至2025年3月31日的財年，毛利率為 3.2%，較去年同期的 3.9% 下降。
截至2025年3月31日的財年，淨收入為 1020 萬美元，或每股基本和稀釋收益 1.84 美元，較去年同期的淨虧損 423 萬美元，或每股基本和稀釋虧損 2.93 美元有所改善。

Fiscal Year 2025 Financial Results

2025 財年財務結果

Revenue

收入

Revenue decreased by$4.02 million, or 3.2%, to$119.97 millionfor the fiscal year endedMarch 31, 2025, from$123.99 millionfor the same period of last year.

截至2025年3月31日的財年，收入較去年同期下降 402 萬美元，或 3.2%，降至 1.1997 億美元，較去年同期的 1.2399 億美元下降。

Revenue from offline wholesale decreased by$5.13 million, or 4.3%, to$118.86 millionfor the fiscal year endedMarch 31, 2025, from$123.99 millionfor the same period of last year. As a local wholesale distributor in pharmaceutical products, the Company's sales are limited to local and neighborhood regions. As the market became competitive, to keep reasonable profitability, the Company abandoned certain wholesales with low gross profit margin in the year ended March 31, 2025.As a result, the wholesale revenue declined.

線下批發收入較去年同期下降 513 萬美元，或 4.3%，降至 1.1886 億美元，較去年同期的 1.2399 億美元下降。作為一家當地藥品批發分銷商，公司的銷售僅限於本地和鄰近地區。隨着市場競爭加劇，為了保持合理的盈利能力，公司在截至2025年3月31日的財年放棄了某些毛利率較低的批發業務。因此，批發收入下降。

Revenue from Online platform increased to$1.11 millionfor the fiscal year endedMarch 31, 2025, fromnilfor the same period of last year. The increased figure reflects Allright's online platform revenue for the month of March, 2025. On February 28, 2025, the Company acquired Ridgeline and its subsidiary, Allright, which is a rapidly growing online and offline wholesale distributor of pharmaceutical and other healthcare products such as health foods, cosmetics and daily necessities in China. Allright actively trades on popular online distribution platforms nationwide. Through these online platforms, the Company sell various medical products to retail pharmacies, clinics and other vendors across the country. Allright also has its own online distribution platform.

截至2025年3月31日的財年，在線平台的收入增加至 111 萬美元，較去年同期的零收入有所增長。增加的數字反映了 Allright 在 2025 年 3 月的在線平台收入。2025年2月28日，公司收購了 Ridgeline 及其子公司 Allright，後者是一家快速增長的藥品及其他醫療產品的線上和線下批發分銷商，產品包括保健食品、化妝品和日常必需品。Allright 在全國範圍內的熱門在線分銷平台上積極交易。通過這些在線平台，公司向全國的零售藥房、診所和其他供應商銷售各種醫療產品。Allright 還擁有自己的在線分銷平台。

Gross profit and gross margin

毛利潤和毛利率

Total cost of goods sold decreased to$116.13 millionfor the fiscal year endedMarch 31, 2025, from$119.12 millionfor the same period of last year. Gross profit decreased by$1.04million, or 21.3%, to$3.84million for the fiscal year endedMarch 31, 2025,from$4.88 millionfor the same period of last year. Overall gross margin decreased by 0.7 percentage points to 3.2% for the fiscal year endedMarch 31, 2025, from 3.9% for the same period of last year.

截至2025年3月31日的財年，商品銷售總成本降至 1.1613 億美元，較去年同期的 1.1912 億美元下降。毛利潤較去年同期下降 104 萬美元，或 21.3%，降至 384 萬美元。整體毛利率較去年同期下降 0.7 個百分點，降至 3.2%。

Gross margins for offline wholesale and online platform were 3.2% and 7.4%, respectively, for the fiscal year endedMarch 31, 2025, compared to gross margins for offline wholesale and online platform of 3.9% and nil%, respectively, for the same period of last year.

截至2025年3月31日的財年，線下批發和在線平台的毛利率分別為 3.2% 和 7.4%，而去年同期線下批發和在線平台的毛利率分別為 3.9% 和零。

Income (Loss) from operations

營業收入（虧損）

Sales and marketing expenses increased by$0.60 million, or 64.2%, to$1.53 millionfor the fiscal year endedMarch 31, 2025,from$0.93 millionfor the same period of last year. The increase was primarily attributable to the increase in drug distribution service fee. Overall, such expenses as a percentage of the Company's revenue were 1.3% and 0.8% respectively, for the years ended March 31, 2025 and 2024.

截至2025年3月31日的財年，銷售和市場營銷費用增加了 60 萬美元，或 64.2%，達到 153 萬美元，較去年同期的 93 萬美元有所增加。增加的主要原因是藥品分銷服務費的增加。總體而言，這些費用佔公司收入的比例分別為 1.3% 和 0.8%，適用於截至 2025 年和 2024 年的財年。

General and administrative expenses decreased by$8,158, or 0.2%, to$3.34million for the fiscal year endedMarch 31, 2025,from$3.35 millionfor the same period of last year. The decrease in general and administrative expenses was primarily due to the decrease in warehousing management fee, offset by the increase in exchange loss of approximately $0.51 million. Such expenses as a percentage of revenue increased for the year ended March 31, 2025 to 2.8% from 2.7% for the same period a year ago. In the year ended March 31, 2025, the Company recorded approximately $0.52 million in warehousing management fee as compared to approximately of $0.99 million in warehousing management fee in the year ended March 31, 2024.

一般和管理費用減少了 8,158 美元，或 0.2%，至 334 萬美元，截止於2025年3月31日的財年，相比於去年同期的 335 萬美元。一般和管理費用的減少主要是由於倉儲管理費的減少，部分被約 51 萬美元的匯兑損失所抵消。截止於2025年3月31日的財年，這些費用佔收入的比例從去年同期的 2.7% 上升至 2.8%。在截止於2025年3月31日的財年，公司記錄的倉儲管理費約為 52 萬美元，而在截止於2024年3月31日的財年為約 99 萬美元。

Loss from operations was$1.04 millionfor the fiscal year endedMarch 31, 2025, compared toincome from operations of $0.60 millionfor the same period of last year. Operating margin was (0.9)% and 0.5% for the fiscal year endedMarch 31, 2025and 2024, respectively.

截止於2025年3月31日的財年，運營損失為 104 萬美元，而去年同期的運營收入為 60 萬美元。運營利潤率分別為（0.9）% 和 0.5%。

Net loss from continuing operations

持續經營的淨損失

Net loss from continuing operations was $1.45millionand $0.79 millionin the years ended March 31, 2025 and 2024.

截止於 2025 年和2024年3月31日的財年，持續經營的淨損失分別為 145 萬美元和 79 萬美元。

Net income (loss)

淨收入（損失）

Net income was$10.20 million, or$1.84per basic and diluted earnings per share for the fiscal year endedMarch 31, 2025, compared to net loss of$4.23 million, or$2.93per basic and diluted loss per share for the same period of last year.

截止於2025年3月31日的財年，淨收入為 1,020 萬美元，或每股基本和稀釋收益 1.84 美元，而去年同期的淨損失為 423 萬美元，或每股基本和稀釋損失 2.93 美元。

Financial Condition

財務狀況

As of March 31, 2025, the Company had cash and cash equivalents of $12.78 million, compared to $2.30 million as of March 31, 2024. Net cash provided by operating activities was $1.25 million for the fiscal year ended March 31, 2025, compared to net cash used in operating activities of $3.16 million for the same period of last year. The change is primarily attributable to an increase in other payables and accrued liabilities of $27.88 million, an increase in accounts receivable of $11.84 million and an increase in net income (loss) of $14.43 million, offset by a decrease in accounts payable of $27.13 million, a decrease in other receivable of $11.09 million and a decrease in gain of divestiture of Jiuxin Investment of $15.76 million.

截至2025年3月31日，公司擁有現金及現金等價物 1,278 萬美元，而截至2024年3月31日為 230 萬美元。截止於2025年3月31日的財年，經營活動提供的淨現金為 125 萬美元，而去年同期的經營活動使用的淨現金為 316 萬美元。變化主要歸因於其他應付款和應計負債增加了 2,788 萬美元，應收賬款增加了 1,184 萬美元，以及淨收入（損失）增加了 1,443 萬美元，部分被應付賬款減少了 2,713 萬美元、其他應收款減少了 1,109 萬美元以及九信投資剝離收益減少了 1,576 萬美元所抵消。

Net cash used in investing activities was$18.14 millionfor the fiscal year endedMarch 31, 2025, compared to$2.04 millionfor the same period of last year. The change is primarily attributable to divestiture of Jiuxin Investment.

截止於2025年3月31日的財年，投資活動使用的淨現金為 1,814 萬美元，而去年同期為 204 萬美元。變化主要歸因於九信投資的剝離。

Net cash provided by financing activities was$1.51 millionfor the fiscal year endedMarch 31, 2025, compared to$8.00 millionfor the same period of last year. The change is primarily due to proceeds from equity and debt financing and change in notes payables issued to Hangzhou United Bank.

截止於2025年3月31日的財年，融資活動提供的淨現金為 151 萬美元，而去年同期為 800 萬美元。變化主要是由於從股權和債務融資中獲得的收益以及向杭州聯合銀行發行的票據的變化。

AboutRidgetech, Inc.

關於 Ridgetech, Inc.

Ridgetech, Inc., formerly known asChina Jo-JoDrugstores, Inc. ("Ridgetech" or the "Company"), is a growing online and offline wholesale distributor of pharmaceutical and other healthcare products in China. Ridgetech actively trades on popular online distribution platforms nationwide and has its own online distribution platform. The Company believes that trading on these platforms offers greater opportunities to distribute pharmaceutical products nationwide. For more information about the Company, please visitwww.ridgetch.com. The Company routinely posts important information on its website.

Ridgetech, Inc.，前身為 China Jo-Jo Drugstores, Inc.（"Ridgetech"或"公司"），是中國一家不斷發展的在線和離線藥品及其他醫療保健產品的批發分銷商。Ridgetech 在全國範圍內的熱門在線分銷平台上積極交易，並擁有自己的在線分銷平台。公司認為，在這些平台上交易提供了更大的機會來在全國範圍內分銷藥品。有關公司的更多信息，請訪問 www.ridgetch.com。公司定期在其網站上發佈重要信息。

Forward-Looking Statements

前瞻性聲明

This press release contains information about the Company's view of its future expectations, plans and prospects that constitute forward-looking statements. Forward-looking statements usually, but not always, contain the words "estimate," "anticipate," "believe," "expect," or similar expressions, or the negative of those words and expressions, as well as statements in future tense. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the Company. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with the Company's ability to secure additional funding, execute its business strategy, and respond to changing market conditions; fluctuations in operating results; the Company's ability to maintain and grow its distribution platforms and customer base; the Company's dependence on key customers; the effectiveness of marketing and business development efforts; the integration of acquired businesses, technologies, or assets; intensifying competition within the pharmaceutical and healthcare distribution industry; evolving government regulations and macro-economic conditions in China and globally; its ability to attract, hire, and retain qualified management and employees; and the adequacy of its intellectual property protection. The Company encourages you to review other factors that may affect its future results in the Company's annual reports and in its other filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or publicly announce revisions to any forward-looking statements to reflect future events or developments, except as required by law.

本新聞稿包含有關公司對其未來預期、計劃和前景的看法，這些內容構成前瞻性聲明。前瞻性聲明通常，但並不總是，包含 “估計”、“預期”、“相信”、“期待” 或類似表達，或這些詞和表達的否定，以及未來時態的陳述。所有前瞻性聲明本質上都是不確定的，因為它們基於對未來事件或公司未來表現的當前預期和假設。實際結果可能因多種因素而與歷史結果或這些前瞻性聲明所指示的結果有重大差異，包括但不限於與公司獲得額外資金、執行其商業戰略和應對市場條件變化的能力相關的風險和不確定性；運營結果的波動；公司維持和擴大其分銷平台和客户基礎的能力；公司對關鍵客户的依賴；市場營銷和業務發展工作的有效性；收購業務、技術或資產的整合；製藥和醫療保健分銷行業的競爭加劇；中國及全球政府法規和宏觀經濟條件的變化；吸引、僱用和留住合格管理人員和員工的能力；以及其知識產權保護的充分性。公司鼓勵您查看可能影響其未來結果的其他因素，這些因素在公司的年度報告和向證券交易委員會的其他文件中有所披露。除法律要求外，公司不承擔更新或公開宣佈對任何前瞻性聲明進行修訂以反映未來事件或發展的義務。

For more information, please contact:

如需更多信息，請聯繫：

Company Contact:

公司聯繫人：

Frank Zhao

Chief Financial Officer

首席財務官

+86-571-88077108

frank.zhao@ridgetch.com

Investor Relations Contact:

投資者關係聯繫人：

Tina Xiao Ascent Investor Relations LLC

+1-646-932-7242

investors@ascent-ir.com


RIDGETECH, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS

	March31,		March31,
	2025		2024
ASSETS
CURRENT ASSETS
Cash and cash equivalents	$	12,779,781		$	2,297,256
Restricted cash		5,761,294			1,988,710
Trade accounts receivables		27,811,813			6,014,511
Inventories		9,758,071			9,076,734
Other receivables, net		2,419,671			218,765
Advances to suppliers		433,140			182,075
Due from related parties		-			19,737
Other current assets		745,477			-
Current assets of discontinued operations		-			49,884,574
Total current assets		59,709,247			69,682,362

NON-CURRENT ASSETS
Property and equipment, net		8,931			8,377
Intangible assets, net		3,302,961			1,276,737
Goodwill		1,463,733			-
Non-current assets of discontinued operations		-			24,089,614
Total non-current assets		4,775,625			25,374,728
Total assets	$	64,484,872		$	95,057,090

LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES
Accounts payable	$	19,666,664		$	30,576,909
Notes payable		10,386,612			6,594,442
Other payables		2,319,139			592,876
Due to related parties		2,130			2,140
Customer deposits		264,068			174,138
Taxes payable		1,521,546			543,081
Accrued liabilities		196,210			197,199
Current liabilities of discontinued operations		-			35,679,310
Total current liabilities		34,356,369			74,360,095

NON-CURRENT LIABILITIES
Deferred tax liabilities		492,121			-
Non-current liabilities of discontinued operations		-			6,403,858
Total non-current liabilities		492,121			6,403,858
Total liabilities		34,848,490			80,763,953

COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS' EQUITY
Ordinary shares; $0.24 par value; 36,000,000,000 shares authorized; 5,855,009 and 1,743,362 shares issued and outstanding as of March 31, 2025 and 2024, respectively		1,405,202			418,407
Preferred shares; $0.001 par value; 10,000,000 shares authorized; nil issued and outstanding as of March 31, 2025 and 2024		-			-
Additional paid-in capital		91,743,163			86,413,978
Statutory reserves		-			1,309,109
Accumulated deficit		(63,312,779)			(73,507,246)
Accumulated other comprehensive income		(199,204)			1,005,762
Total shareholders' equity attributed to Ridgetech		29,636,382			15,640,010
Noncontrolling interests		-			(1,346,873)
Total shareholders' equity		29,636,382			14,293,137
Total liabilities and shareholders' equity	$	64,484,872		$	95,057,090


RIDGETECH, INC. 及其子公司
合併資產負債表

	2025年3月31日		2024年3月31日

資產
流動資產
現金及現金等價物	$	12,779,781		$	2,297,256
限制性現金		5,761,294			1,988,710
應收賬款		27,811,813			6,014,511
存貨		9,758,071			9,076,734
其他應收款，淨額		2,419,671			218,765
預付款項		433,140			182,075
應收關聯方款項		-			19,737
其他流動資產		745,477			-
停業業務的流動資產		-			49,884,574
流動資產總計		59,709,247			69,682,362

非流動資產
淨物業和設備		8,931			8,377
淨無形資產		3,302,961			1,276,737
商譽		1,463,733			-
停業業務的非流動資產		-			24,089,614
非流動資產總計		4,775,625			25,374,728
資產總計	$	64,484,872		$	95,057,090

負債及股東權益
流動負債
應付賬款	$	19,666,664		$	30,576,909
應付票據		10,386,612			6,594,442
其他應付款		2,319,139			592,876
應付關聯方款項		2,130			2,140
客户存款		264,068			174,138
應付税款		1,521,546			543,081
應計負債		196,210			197,199
停業業務的流動負債		-			35,679,310
流動負債總計		34,356,369			74,360,095

非流動負債
遞延所得税負債		492,121			-
停業業務的非流動負債		-			6,403,858
非流動負債總計		492,121			6,403,858
負債總計		34,848,490			80,763,953

承諾與或有事項
股東權益
普通股；面值$0.24；授權 36,000,000,000 股；
截至2025年3月31日和2024年3月31日，已發行和流通 5,855,009 股和 1,743,362 股		1,405,202			418,407
優先股；面值$0.001；授權 10,000,000 股；截至2025年3月31日和2024年3月31日，未發行和流通		-			-
額外實收資本		91,743,163			86,413,978
法定儲備		-			1,309,109
累計虧損		(63,312,779)			(73,507,246)
累計其他綜合收益		(199,204)			1,005,762
歸屬於 Ridgetech 的股東權益總計		29,636,382			15,640,010
非控股權益		-			(1,346,873)
股東權益總計		29,636,382			14,293,137
負債及股東權益總計	$	64,484,872		$	95,057,090


RIDGETECH, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

	For the years ended March 31,
	2025		2024			2023
REVENUES, NET	$	119,971,638		$	123,994,053		$	120,199,193

COST OF GOODS SOLD		116,132,823			119,115,636			116,597,751

GROSS PROFIT		3,838,815			4,878,417			3,601,442

SELLING EXPENSES		1,534,200			934,223			1,266,025
GENERAL AND ADMINISTRATIVE EXPENSES		3,339,954			3,348,112			5,137,741
STOCK BASED COMPENSATION		-			-			10,360,000
TOTAL OPERATING EXPENSES		4,874,154			4,282,335			16,763,766

INCOME (LOSS) FROM OPERATIONS		(1,035,339)			596,082			(13,162,324)

OTHER INCOME (EXPENSES):
INTEREST INCOME		92,834			197,763			31,582
INVESTMENT LOSS		-			(1,607,537)			(2,402,376)
OTHER INCOME (EXPENSES)		(8,155)			(13,377)			92,358

LOSS BEFORE INCOME TAXES		(950,660)			(827,069)			(15,440,760)

PROVISION FOR INCOME TAXES		503,524			(41,363)			394,541
NET LOSS FROM CONTINUING OPERATIONS		(1,454,184)			(785,706)			(15,835,301)
NET LOSS FROM DISCONTINUED OPERATIONS, NET OF TAXES		(4,103,718)			(3,448,536)			(5,303,476)
GAIN OF DIVESTITURE JIUXIN INVESTMENT		15,757,753			-			-
NET GAIN(LOSS) FROM DISCONTINUED OPERATIONS, NET OF TAX		11,654,035			(3,448,536)			(5,303,476)

NET INCOME (LOSS)		10,199,851			(4,234,242)			(21,138,777)

LESS: NET LOSS ATTRIBUTABLE TO NONCONTROLLING INTEREST		5,384			(14)			(252)

NET INCOME (LOSS) ATTRIBUTABLE TO RIDGETECH, INC.		10,194,467			(4,234,228)			(21,138,525)
NET INCOME (LOSS) ATTRIBUTABLE TO RIDGETECH, INC. FROM CONTINUING OPERATIONS		(1,454,184)			(785,706)			(15,835,301)
NET INCOME (LOSS) ATTRIBUTABLE TO RIDGETECH, INC. FROM DISCONTINUED OPERATIONS		11,648,651			(3,448,522)			(5,303,224)

OTHER COMPREHENSIVE LOSS
FOREIGN CURRENCY TRANSLATION ADJUSTMENTS		(1,204,966)			(729,373)			(2,617,857)
COMPREHENSIVE INCOME (LOSS)		8,994,885			(4,963,615)			(23,756,634)

WEIGHTED AVERAGE NUMBER OF SHARES:
Basic		5,543,118			1,444,263			509,828
Diluted		5,543,118			1,444,263			509,828

INCOME (LOSS) PER SHARE:
Basic	$	1.84		$	(2.93)		$	(41.46)
Diluted	$	1.84		$	(2.93)		$	(41.46)


RIDGETECH, INC. 及其子公司
合併經營報表及綜合收益（損失）

	截至
	2025年3月31日		2024 年			2023 年
淨收入	$	119,971,638		$	123,994,053		$	120,199,193

銷售成本		116,132,823			119,115,636			116,597,751

毛利潤		3,838,815			4,878,417			3,601,442

銷售費用		1,534,200			934,223			1,266,025
一般及行政費用		3,339,954			3,348,112			5,137,741
股票基礎補償		-			-			10,360,000
總運營費用		4,874,154			4,282,335			16,763,766

運營收入（損失）		(1,035,339)			596,082			(13,162,324)

其他收入（費用）：
利息收入		92,834			197,763			31,582
投資損失		-			(1,607,537)			(2,402,376)
其他收入（費用）		(8,155)			(13,377)			92,358

税前損失		(950,660)			(827,069)			(15,440,760)

所得税費用		503,524			(41,363)			394,541
持續經營的淨損失		(1,454,184)			(785,706)			(15,835,301)
停業經營的淨損失，
扣除税費		(4,103,718)			(3,448,536)			(5,303,476)
處置 Jiuxin 投資的收益		15,757,753			-			-
停業經營的淨收益（損失），扣除税費		11,654,035			(3,448,536)			(5,303,476)

淨收益（損失）		10,199,851			(4,234,242)			(21,138,777)

減：歸屬於
非控股權益的淨損失		5,384			(14)			(252)

歸屬於 RIDGETECH, INC. 的淨收益（損失）		10,194,467			(4,234,228)			(21,138,525)
歸屬於 RIDGETECH, INC. 的持續經營的淨收益（損失）		(1,454,184)			(785,706)			(15,835,301)
歸屬於 RIDGETECH, INC. 的停業經營的淨收益（損失）		11,648,651			(3,448,522)			(5,303,224)

其他綜合損失
外幣翻譯調整		(1,204,966)			(729,373)			(2,617,857)
綜合收益（損失）		8,994,885			(4,963,615)			(23,756,634)

加權平均股份數：
基本		5,543,118			1,444,263			509,828
稀釋		5,543,118			1,444,263			509,828

每股收益（損失）：
基本	$	1.84		$	(2.93)		$	(41.46)
稀釋	$	1.84		$	(2.93)		$	(41.46)


RIDGETECH, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS

	For the years ended March 31,
	2025		2024			2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	10,199,851		$	(4,234,242)		$	(21,138,777)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		1,137,240			790,449			718,002
Bad debt direct write-off and provision and reversal		85,642			(249,257)			7,579,886
Amortization of right-of-use assets		4,879,012			4,594,172			-
Loss from disposal of property and equipment		-			107,251			-
Gain of divestiture Jiuxin Investment		(15,757,753)			-			-
Deferred tax expenses(benefits)		(29,822)
Share-based compensation		-			-			10,360,000
Investment loss		-			1,607,537			2,402,376
Change in operating assets and liabilities:
Accounts receivable		10,040,414			(1,804,440)			(2,531,755)
Notes receivable		(29,271)			19,943			(20,861)
Inventories and biological assets		405,822			(1,699,621)			(522,550)
Other receivables		(11,758,658)			(672,830)			(958,671)
Advances to suppliers		(341,702)			(839,221)			201,984
Long term deposit		(1,361,613)			(132,568)			589,653
Other current assets		-			19,076			331,426
Other noncurrent assets		(359,114)			69,539			(30,483)
Amount due from related parties		-			(317,828)			-
Accounts payable		(21,128,762)			6,002,186			1,765,488
Other payables and accrued liabilities		28,752,570			868,975			(1,426,829)
Customer deposits		(162,940)			(144,761)			(1,035,456)
Taxes payable		1,314,644			(948,277)			433,054
Operating lease liabilities		(4,637,790)			(6,191,522)			-
Net cash provided by (used in) operating activities		1,247,770			(3,155,439)			(3,283,513)

CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of equipment and building		(155,360)			(330,677)			(118,272)
Investment in a joint venture		-			(1,116,212)			(4,379)
Purchases of intangible assets		-			(66,973)			(12,774)
Additions to leasehold improvements		(459,907)			(525,988)			(180,672)
Acquisition of Ridgeline, net of cash acquired		4,833,439			-			-
Divestiture Jiuxin Investment, net of cash disposed		(22,353,250)			-			-
Net cash used in investing activities		(18,135,078)			(2,039,850)			(316,097)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from short-term bank loan		-			1,116,212			-
Repayment of short-term bank loan		(277,266)			(837,159)			-
Repayment of third parties loan		-			-			(1,811,558)
Proceeds from notes payable		51,689,531			56,875,403			57,965,013
Repayment of notes payable		(56,365,693)			(52,997,171)			(60,273,598)
Proceeds from issuance of shares and warrants in private placements		7,633,000			2,589,600			7,325,000
Proceeds from other payable-related parties		325,784			1,257,406			43,785
Repayment of other payable-related parties		(1,499,764)			-			(882,486)
Net cash provided by financing activities		1,505,592			8,004,291			2,366,156

EFFECT OF EXCHANGE RATE ON CASH		1,048,620			(1,505,475)			(2,535,479)

DECREASE (INCREASE) IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH		(14,333,096)			1,303,527			(3,768,933)
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, beginning of year		32,874,171			31,570,644			35,339,577
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, end of year	$	18,541,075		$	32,874,171		$	31,570,644

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for income taxes	$	137,456		$	149,023		$	63,668
Cash paid for interest		6,289			13,604			64,943

NON-CASH ACTIVITIES：
Cashless exercise of warrants	$	-		$	-		$	135,118
Issuance of shares for acquisition of subsidiaries		3,582,250			-			-
Cancellation of shares for disposal of subsidiaries		4,102,848			-			-


RIDGETECH, INC. 及其子公司
合併現金流量表

	截至
2025年3月31日的年度
	2025		2024			2023
經營活動產生的現金流量：
淨虧損	$	10,199,851		$	(4,234,242)		$	(21,138,777)
調整淨虧損以對賬用於經營活動的淨現金：
折舊和攤銷		1,137,240			790,449			718,002
壞賬直接沖銷及準備金和衝回		85,642			(249,257)			7,579,886
使用權資產攤銷		4,879,012			4,594,172			-
處置物業和設備的損失		-			107,251			-
處置九信投資的收益		(15,757,753)			-			-
遞延税費（收益）		(29,822)
基於股份的補償		-			-			10,360,000
投資損失		-			1,607,537			2,402,376
經營資產和負債的變動：
應收賬款		10,040,414			(1,804,440)			(2,531,755)
應收票據		(29,271)			19,943			(20,861)
存貨和生物資產		405,822			(1,699,621)			(522,550)
其他應收款		(11,758,658)			(672,830)			(958,671)
預付款項		(341,702)			(839,221)			201,984
長期存款		(1,361,613)			(132,568)			589,653
其他流動資產		-			19,076			331,426
其他非流動資產		(359,114)			69,539			(30,483)
應收關聯方款項		-			(317,828)			-
應付賬款		(21,128,762)			6,002,186			1,765,488
其他應付款和應計負債		28,752,570			868,975			(1,426,829)
客户存款		(162,940)			(144,761)			(1,035,456)
應付税款		1,314,644			(948,277)			433,054
經營租賃負債		(4,637,790)			(6,191,522)			-
經營活動提供（使用）的淨現金		1,247,770			(3,155,439)			(3,283,513)

投資活動產生的現金流量：
設備和建築物的收購		(155,360)			(330,677)			(118,272)
對合資企業的投資		-			(1,116,212)			(4,379)
無形資產的購買		-			(66,973)			(12,774)
租賃改善的增加		(459,907)			(525,988)			(180,672)
收購 Ridgeline，扣除收購現金		4,833,439			-			-
處置九信投資，扣除處置現金		(22,353,250)			-			-
投資活動使用的淨現金		(18,135,078)			(2,039,850)			(316,097)

融資活動產生的現金流量：
短期銀行貸款的收入		-			1,116,212			-
短期銀行貸款的償還		(277,266)			(837,159)			-
第三方貸款的償還		-			-			(1,811,558)
應付票據的收入		51,689,531			56,875,403			57,965,013
應付票據的償還		(56,365,693)			(52,997,171)			(60,273,598)
私募發行股份和認股權證的收入		7,633,000			2,589,600			7,325,000
其他應付款 - 關聯方的收入		325,784			1,257,406			43,785
其他應付款 - 關聯方的償還		(1,499,764)			-			(882,486)
融資活動提供的淨現金		1,505,592			8,004,291			2,366,156

匯率對現金的影響		1,048,620			(1,505,475)			(2,535,479)

現金及現金等價物和受限現金的減少（增加）		(14,333,096)			1,303,527			(3,768,933)
現金及現金等價物和受限現金，年初		32,874,171			31,570,644			35,339,577
現金及現金等價物和受限現金，年末	$	18,541,075		$	32,874,171		$	31,570,644

現金流量信息的補充披露：
支付的所得税	$	137,456		$	149,023		$	63,668
支付的利息		6,289			13,604			64,943

非現金活動：
無現金行使認股權證	$	-		$	-		$	135,118
為收購子公司而發行股份		3,582,250			-			-
為處置子公司而取消股份		4,102,848			-			-


(a)		The cash flows related to discontinued operations have not been segregated. Accordingly, the Consolidated Statements of Cash Flows include the results of continuing and discontinued operations.


(a)		與終止運營相關的現金流未被分開。因此，合併現金流量表包括持續運營和終止運營的結果。

SOURCE Ridgetech, Inc.

來源 Ridgetech, Inc.

Ridgetech 公司發佈 2025 財年財務報告 | RDGT 股票新聞